BSF Enterprise Plc(BSFAF)
USD --+0.00%
Reward39Moderate
Risk76High
📊75%Data
Revenue growing 815% YoY
BSFAF
+0.0 · +0.00%
USD · PINK
BSF Enterprise Plc | Healthcare
Capital Destroyer
Market Cap:2.67M
ℹ️
Reward Rating
39
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
76
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BSFAF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BSF Enterprise Plc?

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong.

BSFAF · Verdict

Limited reward · high risk

BSFAF has limited near-term tailwinds — volatility and cash flow weigh on the model output.

Based on 88% data coverage

BSFAF · Verdict

What’s working & what to watch

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Cash flow6/100

    -1928% free-cash-flow margin

  • Profitability9/100

    -2107% net margin · -38% ROE

  • Growth41/100

    Earnings +6.2% CAGR

Model-based scoring. For information only — not financial advice.

What is BSF Enterprise Plc?

BSF Enterprise Plc, together with its subsidiaries, develops and commercializes cell-based tissue engineering solutions in the United Kingdom and Hong Kong. The company acquires businesses in the biotechnology, marketing, and e-commerce sectors. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.67M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.67M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0822
52 Week Low0.0029
Last AnnualSeptember
IPO DateN/A
IncorporatedUSA
Shares Outstanding167M
No. of Employees14
IndustryBiotechnology
ExchangePINK
Beta3.141
CurrencyUSD · Reports in GBP